MMP Inhibitors: Past, present and future.
Front Biosci (Landmark Ed)
; 20(7): 1164-78, 2015 06 01.
Article
em En
| MEDLINE
| ID: mdl-25961551
ABSTRACT
Development of inhibitors of matrix metalloproteinases (MMPs) has been fraught with challenges. Early compounds largely failed due to poor selectivity and bioavailability. Dose-limiting side effects, off-target interactions, and improperly designed clinical trials significantly impeded clinical success. As information becomes available and technology evolves, tools to combat these obstacles have been developed. Improved methods for high throughput screening and drug design have led to identification of compounds exhibiting high potency, binding affinity, and favorable pharmacokinetic profiles. Current research into MMP inhibitors employs innovative approaches for drug delivery methods and allosteric inhibitors. Such innovation is key for development of clinically successful compounds.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Peptidomiméticos
/
Inibidores de Metaloproteinases de Matriz
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article